Date: 2013-10-22
Type of information: R&D agreement
Compound: hits against oncology-relevant kinases of therapeutic interest to Boehringer Ingelheim
Company: Beactica (Sweden) Boehringer Ingelheim (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: * On October 22, 2013, Beactica has announced that it has expanded its collaboration with Boehringer Ingelheim. For the additional project, Beactica will use its proprietary fragment-based platform to identify novel and selective hits against oncology-relevant kinases of therapeutic interest to Boehringer Ingelheim.
Beactica\'s collaboration with Boehringer Ingelheim was established in 2008. Previous work under the collaboration includes the contribution of important insights into the interaction mechanism of Giotrif® (afatinib), a treatment that has been recently approved for lung cancer patients with EGFR mutations in Europe and the US.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
